2 completed, 2 recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 2 |
Follow GSK656: new trials by email Literature Review of GSK656 trials Research Report on GSK656
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| PanACEA - STEP2C -01 BTZ-043, Rifampicin, Isoniazid - Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis | Phase 2 | Recruiting | Michael Hoelscher | 390 | 2023-04-14 | 2025-10-07 |
| Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis GSK3036656, Bedaquiline, Delamanid - Tuberculosis | Phase 2 | Completed | GlaxoSmithKline | 127 | 2022-07-26 | 2026-06-17 |
| An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis GSK3036656, Rifafour e-275 - Tuberculosis | Phase 2 | Completed | GlaxoSmithKline | 76 | 2019-03-22 | 2023-10-26 |
Tuberculosis, Pulmonary (4) · Tuberculosis (3)
GlaxoSmithKline (2) · Michael Hoelscher (1) · University College, London (1)
South Africa (4) · Tanzania (2) · Uganda (2) · Gabon (1) · Malawi (1) · Moldova (1) · Mozambique (1) · Vietnam (1)
Michael Hoelscher, Prof Dr. (1)